高级检索
当前位置: 首页 > 详情页

Survival outcomes of stage I colorectal cancer: development and validation of the ACEPLY model using two prospective cohorts

文献详情

资源类型:
Pubmed体系:
机构: [1]Colorectal Cancer Center, Department of General Surgery, West China Hospital,Sichuan University, Chengdu, China [2]West China School of Public Healthand West China Fourth Hospital, Sichuan University, Chengdu, China [3]KeyLaboratory of Carcinogenesis and Translational Research (Ministry of Education),Department of Unit III & Ostomy Service, Gastrointestinal Cancer Centre,Peking University Cancer Hospital & Institute, Beijing, China [4]Departmentof Vascular Surgery, West China Hospital, West China School of Medicine,Sichuan University, Chengdu, China [5]Key Laboratory of Ministry of Educationfor Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China [6]Departmentof Epidemiology and Medical Statistics, West China School of PublicHealth and West China Fourth Hospital, Sichuan University, Chengdu, China [7]Department of Big Data in Health Science, School of Public Health, Centerof Clinical Big Data and Analytics of The Second Affiliated Hospital, ZhejiangUniversity School of Medicine, Hangzhou, China [8]Centre for Global Health,Usher Institute, The University of Edinburgh, Edinburgh, UK [9]Departmentof Oncology, West China School of Public Health and West China FourthHospital, Sichuan University, Chengdu, China
出处:

关键词: Colorectal cancer Early stage Prognosis Risk factor Prediction model

摘要:
Approximately 10% of stage I colorectal cancer (CRC) patients experience unfavorable clinical outcomes after surgery. However, little is known about the subset of stage I patients who are predisposed to high risk of recurrence or death. Previous evidence was limited by small sample sizes and lack of validation.We aimed to identify early indicators and develop a risk stratification model to inform prognosis of stage I patients by employing two large prospective cohorts. Prognostic factors for stage II tumors, including T stage, number of nodes examined, preoperative carcinoma embryonic antigen (CEA), lymphovascular invasion, perineural invasion (PNI), and tumor grade were investigated in the discovery cohort, and significant findings were further validated in the other cohort. We adopted disease-free survival (DFS) as the primary outcome for maximum statistical power and recurrence rate and overall survival (OS) as secondary outcomes. Hazard ratios (HRs) were estimated from Cox proportional hazard models, which were subsequently utilized to develop a multivariable model to predict DFS. Predictive performance was assessed in relation to discrimination, calibration and net benefit.A total of 728 and 413 patients were included for discovery and validation. Overall, 6.7% and 4.1% of the patients developed recurrences during follow-up. We identified consistent significant effects of PNI and higher preoperative CEA on inferior DFS in both the discovery (PNI: HR = 4.26, 95% CI: 1.70-10.67, p = 0.002; CEA: HR = 1.46, 95% CI: 1.13-1.87, p = 0.003) and the validation analysis (PNI: HR = 3.31, 95% CI: 1.01-10.89, p = 0.049; CEA: HR = 1.58, 95% CI: 1.10-2.28, p = 0.014). They were also significantly associated with recurrence rate. Age at diagnosis was a prominent determinant of OS. A prediction model on DFS using Age at diagnosis, CEA, PNI, and number of LYmph nodes examined (ACEPLY) showed significant discriminative performance (C-index: 0.69, 95% CI:0.60-0.77) in the external validation cohort. Decision curve analysis demonstrated added clinical benefit of applying the model for risk stratification.PNI and preoperative CEA are useful indicators for inferior survival outcomes of stage I CRC. Identification of stage I patients at high risk of recurrence is feasible using the ACEPLY model, although the predictive performance is yet to be improved.© 2022. The Author(s).

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 1 区 医学
小类 | 1 区 医学:内科
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 医学:内科
第一作者:
第一作者机构: [1]Colorectal Cancer Center, Department of General Surgery, West China Hospital,Sichuan University, Chengdu, China [2]West China School of Public Healthand West China Fourth Hospital, Sichuan University, Chengdu, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43377 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号